Drug intelligence / Profile preview

BHV-1440

Development stage: Preclinical
Lead developer: Biohaven
Modality: PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
Administration: Subcutaneous

Overview

BHV-1440 is an investigational drug developed by Biohaven, leveraging its proprietary TRAP™ (Targeted Receptor-mediated Antibody Proteolysis) degrader platform. It is designed as a specific degrader of TSHR autoantibodies, aiming to remove these disease-causing proteins. BHV-1440 is being developed as a next-generation immune therapy for the treatment of Graves' disease and thyroid eye disease.

Targets

TSHR (Thyroid-stimulating hormone receptor)

Beyond the preview

Go deeper on BHV-1440.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BHV-1440.

Explore the full profile